Mycophenolate Mofetil Articles
Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus
26 April 2012
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
FDA calls for warning on Roche’s Cellcept
17 August 2009
Japan stock market week to June 8, 2009
9 June 2009
Rituxan fails Ph III lupus nephritis trial
16 March 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
Study suggests TDM for at-risk CellCept patients
18 August 2008
FDA reissues warning on mycopheno drugs
26 May 2008
Stock Commentary - Europe - week to April 14, 2008
21 April 2008
FDA starts safety review of Roche's CellCept and Novartis' Myfortic after cases of PML
21 April 2008
Myfortic cuts GI effects in transplant recipients
14 January 2008
Teva's generic CellCept gets CHMP OK
24 December 2007
Roche updates CellCept warning label
5 November 2007
Aspreva/Roche
15 October 2007
Aspreva/Roche change & extend CellCept deal
10 September 2007
CellCept falls short in Phase III trial
9 July 2007
Aspreva's CellCept granted US fast track review
11 June 2007
Roche 1st-qtr at top end of expectations
23 April 2007
Data supports CellCept transplant regimen
9 April 2007
Aspreva's CellCept misses endpoints in Ph III MG trial
6 November 2006
Aspreva's revenue $76M in 2005
20 February 2006
Aspreva and Roche's CellCept gains orphan status
9 January 2006
Roche/Aspreva's CellCept enters LN trial
8 August 2005
Positive data for CellCept in children
18 April 2005
Aspreva's CellCept enters Ph III MG study
13 September 2004
Positive new data for Roche's CellCept
22 March 2004
Novartis' Myfortic cleared by FDA
8 March 2004
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
New data on Novartis transplant drugs
6 May 2002
CellCept switch boosts renal function
6 May 2002
Dip in 1st-qtr pharma sales at Roche
11 April 2001
Net income leaps 50% at Roche in 2000, but pharma sales disappoint
28 February 2001
Roche plans Tamiflu launch in Japan soon
23 January 2001
Roche names GSK's Abercrombie to heard N Amer pharma ops
12 January 2001
Roche wins new Euro label for Cellcept
15 November 2000
SangStat wins Thymoglobulin OK in Italy
4 September 2000
Roche's CellCept gets expanded label in USA
10 August 2000
Roche's Zenapax approved by the European Commission
4 March 1999
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
CellCept Approved For Heart Transplants In EU
21 August 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Roche's Cellcept Cleared For Heart Transplants
26 February 1998
Roche's Zenapax Effective In Uveitis
19 February 1998
CellCept Use Should Be Broadened, Says Panel
20 January 1998
Roche's Zenapax Gets First Approval For Transplants
17 December 1997
Roche's Zenapax Gets Backing Of FDA Panel
23 October 1997
Solid First Half At Roche As Posicor Is Approved
16 July 1997
Roche And PDL Report Positive Data With Zenapax
19 May 1997
First-Quarter Sales At Roche Up 18%
21 April 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
Roche Impresses At Analysts' Meeting
17 February 1997
Roche's 1996 Sales Ahead Of Expectations
27 January 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Roche Posts 10% 9 Mths Sales Gain
21 October 1996
1996 First-Half Sales In Line At Roche
22 July 1996
EMEA 1995-95: A Crucial Period of Transition
25 March 1996
Brussels Probes Roche Austrian "Subsidy"
4 March 1996
EU CPMP Plenary Meeting In February
26 February 1996
EMEA Approves Roche's CellCept
26 February 1996
Mycophenolate Approval in Europe Imminent, Says Roche
19 February 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
Strong Pharma Growth Offsets Currency At Roche
16 October 1995
US FDA Approving Fewer NMEs, But Faster, In 1995
11 September 1995
CellCept Launched In 1st Market
3 July 1995
First Approval For Roche's Mycophenolate Mofetil
15 May 1995
FDA Panel Backs Cellcept For Acute Rejection
10 April 1995
FDA Panel Backs Oral Ganciclovir
28 November 1994
SANDIMMUN SET FOR DECLINE, SAYS ANALYST
27 June 1994
SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS
24 January 1994
FERMENTATION PLANT FOR SYNTEX AND ANTIBIOTICOS
27 September 1993
NEW YORK STOCK COMMENT
14 June 1993
SYNTEX PROFITS HIT BY RESTRUCTURING
7 June 1993
Showing 1-100 of 100 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
